Obe-cel in Refractory Progressive Forms of Multiple Sclerosis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE1

Total Enrollment

18 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-08-04

Study Completion Date

2029-08-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The main purpose of this study is to evaluate if obe-cel is safe or causes any side effects in adults with refractory progressive MS. The study also plans to assess if obe-cel can show early signs of efficacy in MS. The trial includes only 1 group of patients (single-arm). The study population comprises patients with progressive forms of MS, not responsive to highly effective therapies.

Upon confirmation of study eligibility, patients will receive fludarabine and cyclophosphamide (types of chemotherapy, used here for lymphodepletion) over 1 to 3 days in preparation for receiving a single obe-cel infusion.

Patients will be checked closely in the 28 days following obe-cel treatment. After this, patients will be monitored to evaluate safety and efficacy up to 24 months.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study of Obexelimab in Patients With Relapsing Multiple Sclerosis (MoonStone)

NCT06564311

Relapsing Multiple Sclerosis

ACTIVE_NOT_RECRUITING PHASE2

A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS)

NCT07074886

Multiple Sclerosis

RECRUITING PHASE2

An Extension Study to Assess Impact of Multiple Sclerosis (MS) on Physical Function and Provide Continued Ocrelizumab Treatment

NCT06675955

Multiple Sclerosis

RECRUITING PHASE3

An Open-label Study to Assess the Safety, Efficacy, and Cellular Kinetics of YTB323 in Relapsing Multiple Sclerosis

NCT06617793

Relapsing Multiple Sclerosis

RECRUITING PHASE1/PHASE2

A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis

NCT01194570

Multiple Sclerosis, Primary Progressive

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a Phase 1 study to determine the safety, tolerability, and preliminary efficacy of obe-cel in participants with refractory progressive forms of multiple sclerosis.

The study comprises 3 periods:

Screening Period: From Day -30 to enrolment Treatment Period: From day of enrolment to End of Treatment (EOT) or Day 1 - Patients will be evaluated to confirm eligibility for lymphodepletion, and thereafter receive lymphodepletion to enhance treatment efficacy and CD19 chimeric antigen receptor (CAR) T cell survival.

Obe-cel Administration: If the participant's eligibility for receiving obe-cel infusion is confirmed, the participant is to receive a single obe cel infusion on Day 1.

Post treatment Period: From Day 1 to End of Study all participants will be followed up for efficacy and safety evaluation.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Progressive Multiple Sclerosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Single-arm, single group assignment, open-label

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Obecabtagene autoleucel (obe-cel)

Group Type EXPERIMENTAL

Obecabtagene autoleucel (obe-cel)

Intervention Type BIOLOGICAL

Obecabtagene autoleucel (obe-cel) given as a single infusion.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Obecabtagene autoleucel (obe-cel)

Obecabtagene autoleucel (obe-cel) given as a single infusion.

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Willing and able to give written informed consent for participation in the study.
* Ability and willingness to adhere to the protocol's Schedule of Activities and other requirements.
* Participants must be 18 to 60 years of age inclusive at the time of signing the informed consent form.
* A female participant is eligible to participate if she is not pregnant or breastfeeding.
* Current diagnosis of PMS.
* Must have been treated previously with 2 disease-modifying therapies

Exclusion Criteria

* Any medications prohibited by the protocol.
* Highly active multiple sclerosis.
* Diagnosis of another autoimmune central nervous system condition.
* Active or uncontrolled fungal, bacterial, viral infection.
* History of malignant neoplasms unless disease-free for at least 24 months.
* History of heart, lung, kidney, liver transplant or hematopoietic stem cell transplant.

Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No